All Phenotypes Cdkn2a<tm1.1Brn> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Cdkn2a^tm1.1Brn
targeted mutation 1.1, Anton Berns
MGI:2384165

Summary

10 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn	involves: 129P2/OlaHsd * FVB/N	MGI:3766055
cn2	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S7/SvEvBrd	MGI:3850439
cn3	Cdkn2a^tm1.1Brn/Cdkn2a⁺ Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S7/SvEvBrd	MGI:3850449
cn4	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S7/SvEvBrd	MGI:3850451
cn5	Braf^tm1.1Brd/Braf⁺ Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Tg(Vil1-cre)997Gum/0	involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL	MGI:5528298
cn6	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth	involves: 129P2/OlaHsd * FVB/N	MGI:3850412
cn7	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth Ptgds^{tm1.1(cre)Gvn}/Ptgds⁺	involves: 129P2/OlaHsd * FVB/N	MGI:5051643
cx8	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Pknox1^tm1Fbla/Pknox1^tm1Fbla Trp53^tm1Tyj/Trp53^tm1Tyj	involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:4839565
cx9	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Pknox1^tm1Fbla/Pknox1^tm1Fbla	involves: 129/Sv * 129P2/OlaHsd * C57BL/6	MGI:4839469
cx10	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm2Brn/Cdkn2b^tm2Brn	involves: 129P2/OlaHsd * FVB/N	MGI:3766049

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn
Genetic Background	involves: 129P2/OlaHsd * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:71393 )

N	• mice display no increased predisposition to developing tumors and do not exhibit any defects in cell cycle regulation

decreased incidence of tumors by chemical induction ( J:125189 )

• DMBA-induced tumors occur later and exhibit a much narrower diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn homozygotes

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:125189 )

• DMBA-induced tumors occur later and exhibit a much narrower diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn homozygotes

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn
Genetic Background	involves: 129P2/OlaHsd * 129S7/SvEvBrd

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)
Nf2^tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:132943 )

• following adenoviral cre treatment, median survival time is 80 days

neoplasm

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 100% of mice develop highly invasive thoracic tumors (including malignant mesotheliomas, 47 of 51; rhabdomyosarcomas, 4 of 51; and schwannomas, 1 of 51)

• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased rhabdomyosarcoma incidence ( J:132943 )

increased mesothelioma incidence ( J:132943 )

increased Schwannoma incidence ( J:132943 )

nervous system

increased Schwannoma incidence ( J:132943 )

muscle

increased rhabdomyosarcoma incidence ( J:132943 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a⁺ Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn
Genetic Background	involves: 129P2/OlaHsd * 129S7/SvEvBrd

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased metastatic potential ( J:132943 )

• following adenoviral cre treatment, the parietal pleura often shows invasion with concomitant pleural effusion

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 94% of mice develop aggressive thoracic tumors (including malignant mesotheliomas, 15 of 51; and rhabdomyosarcomas, 1 of 51) with the parietal pleura often showing invasion with concomitant pleural effusion

• following adenoviral cre treatment, 1% of mice develop aspecific tumors not induced by adeno-cre treatment

increased rhabdomyosarcoma incidence ( J:132943 )

increased mesothelioma incidence ( J:132943 )

homeostasis/metabolism

pleural effusion ( J:132943 )

• following adenoviral cre treatment, the parietal pleura often shows invasion with concomitant pleural effusion

respiratory system

pleural effusion ( J:132943 )

• following adenoviral cre treatment, the parietal pleura often shows invasion with concomitant pleural effusion

muscle

increased rhabdomyosarcoma incidence ( J:132943 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Trp53^tm1Brn/Trp53^tm1Brn
Genetic Background	involves: 129P2/OlaHsd * 129S7/SvEvBrd

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased mesothelioma incidence ( J:132943 )

• following adenoviral cre treatment, 2 of 13 mice develop malignant mesotheliomas-like thoracic tumors

Allelic Composition	Braf^tm1.1Brd/Braf⁺ Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Tg(Vil1-cre)997Gum/0
Genetic Background	involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braf^tm1.1Brd mutation (0 available); any Braf mutation (58 available)
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)
Tg(Vil1-cre)997Gum mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased intestinal adenoma incidence ( J:199307 )

• 1.3 fold increase in serrated adenomas relative to mice with unmutated Cdkn2a alleles (not statistically significant)

increased carcinoma incidence ( J:199307 )

• 6.4 fold increase in carcinomas relative to mice with unmutated Cdkn2a alleles

digestive/alimentary system

increased intestinal adenoma incidence ( J:199307 )

• 1.3 fold increase in serrated adenomas relative to mice with unmutated Cdkn2a alleles (not statistically significant)

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth
Genetic Background	involves: 129P2/OlaHsd * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased liver tumor incidence ( J:131179 )

• following adenoviral cre treatment, liver tumor development is increased compared to in untreated mice (on average 18% from 3%)

osseous metaplasia ( J:131179 )

• following treatment with adenoviral cre, 15% of mice exhibit osseous metaplasia compared to 2% of wild-type mice

increased meningioma incidence ( J:131179 )

• following treatment with adenoviral cre, meningioma development is increased compared to in untreated mice (on average 37% from 13%)

• meningiomas in adenoviral cre-treated mice share radiological features with human meningiomas

increased osteoma incidence ( J:131179 )

• following treatment with adenoviral cre, osteoma development is increased compared to in untreated mice (on average 78% from 57%)

nervous system

increased meningioma incidence ( J:131179 )

• following treatment with adenoviral cre, meningioma development is increased compared to in untreated mice (on average 37% from 13%)

• meningiomas in adenoviral cre-treated mice share radiological features with human meningiomas

hydrocephaly ( J:131179 )

• following adenoviral cre treatment, hydrocephalus is increased compared to in untreated mice (on average 56% from 36%)

abnormal meninges morphology ( J:131179 )

• following adenoviral cre treatment, meningothelial proliferation is increased compared to in untreated mice (on average 77% from 46%)

skeleton

increased osteoma incidence ( J:131179 )

• following treatment with adenoviral cre, osteoma development is increased compared to in untreated mice (on average 78% from 57%)

liver/biliary system

increased liver tumor incidence ( J:131179 )

• following adenoviral cre treatment, liver tumor development is increased compared to in untreated mice (on average 18% from 3%)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
familial meningioma		DOID:4586		J:131179

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth Ptgds^{tm1.1(cre)Gvn}/Ptgds⁺
Genetic Background	involves: 129P2/OlaHsd * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)
Nf2^tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Ptgds^{tm1.1(cre)Gvn} mutation (0 available); any Ptgds mutation (15 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

nervous system

increased meningioma incidence ( J:173718 )

• mice develop a slightly higher number of meningiomas (not statistically significant) relative to Cdkn2a-sufficient animals

mortality/aging

mortality/aging ( J:173718 )

N	• mice show similar survival/lifespan to Cdkn2a-sufficient animals

neoplasm

neoplasm ( J:173718 )

N	• no pituitary tumors are observed

increased meningioma incidence ( J:173718 )

• mice develop a slightly higher number of meningiomas (not statistically significant) relative to Cdkn2a-sufficient animals

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Pknox1^tm1Fbla/Pknox1^tm1Fbla Trp53^tm1Tyj/Trp53^tm1Tyj
Genetic Background	involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)
Pknox1^tm1Fbla mutation (0 available); any Pknox1 mutation (90 available)
Trp53^tm1Tyj mutation (12 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

preweaning lethality, complete penetrance ( J:165811 )

• no mice are recovered (no time of death given)

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Pknox1^tm1Fbla/Pknox1^tm1Fbla
Genetic Background	involves: 129/Sv * 129P2/OlaHsd * C57BL/6

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

embryo

abnormal pluripotent precursor cell morphology ( J:165811 )

• mice exhibit the same reduced Oct4 expression domain as in Pknox1^tm1Fbla homozygotes

Allelic Composition	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm2Brn/Cdkn2b^tm2Brn
Genetic Background	involves: 129P2/OlaHsd * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm1.1Brn mutation (1 available); any Cdkn2a mutation (62 available)
Cdkn2b^tm2Brn mutation (0 available); any Cdkn2b mutation (7 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:125189 )

N	• untreated mice do not show any increased susceptibility to tumor formation within the first year

increased incidence of tumors by chemical induction ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces the same tumors as observed in Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn/Cdkn2b^tm1Brn Tg(ACTB-cre)2Mrt mice

• DMBA-induced tumors occur earlier and exhibit a much broader diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn homozygotes

increased skin tumor incidence ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces skin tumors

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces the same tumors as observed in Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn/Cdkn2b^tm1Brn Tg(ACTB-cre)2Mrt mice

• DMBA-induced tumors occur earlier and exhibit a much broader diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn homozygotes

integument

increased skin tumor incidence ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces skin tumors

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/23/2024 MGI 6.23